{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:28:00Z","timestamp":1776302880163,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01025-w","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T20:51:28Z","timestamp":1738702288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and Pregnancy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-8513","authenticated-orcid":false,"given":"Iain","family":"Gardner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki T.","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd Wei Tat","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Lapham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theunis C.","family":"Goosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.eplepsyres.2018.01.011","volume":"140","author":"V Petrenaite","year":"2018","unstructured":"Petrenaite V, Ohman I, Ekstrom L, Saebye D, Hansen TF, Tomson T, et al. UGT polymorphisms and lamotrigine clearance during pregnancy. Epilepsy Res. 2018;140:199\u2013208. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.01.011.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1025_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","volume":"18","author":"TW May","year":"1996","unstructured":"May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1996;18(5):523\u201331. https:\/\/doi.org\/10.1097\/00007691-199610000-00001.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1025_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos. 2006;34(6):1055\u201362. https:\/\/doi.org\/10.1124\/dmd.106.009340.","journal-title":"Drug Metab Dispos"},{"issue":"2\u20133","key":"1025_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","volume":"57","author":"BE Gidal","year":"2003","unstructured":"Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res. 2003;57(2\u20133):85\u201393. https:\/\/doi.org\/10.1016\/j.eplepsyres.2003.09.008.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1025_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/00498250902745082","volume":"39","author":"UA Argikar","year":"2009","unstructured":"Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009;39(5):355\u201363. https:\/\/doi.org\/10.1080\/00498250902745082.","journal-title":"Xenobiotica"},{"issue":"9","key":"1025_CR6","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1124\/dmd.109.028225","volume":"37","author":"O Kerdpin","year":"2009","unstructured":"Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO. Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009;37(9):1948\u201355. https:\/\/doi.org\/10.1124\/dmd.109.028225.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1025_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1208\/s12248-024-00978-8","volume":"26","author":"LWT Tang","year":"2024","unstructured":"Tang LWT, Lapham K, Goosen TC. UGT2B10 is the major UDP-glucuronosyltransferase 2B isoform involved in the metabolism of lamotrigine and is implicated in the drug-drug interaction with valproic acid. AAPS J. 2024;26(6):107. https:\/\/doi.org\/10.1208\/s12248-024-00978-8.","journal-title":"AAPS J"},{"issue":"2","key":"1025_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/dmd.118.084301","volume":"47","author":"J Badee","year":"2019","unstructured":"Badee J, Qiu N, Parrott N, Collier AC, Schmidt S, Fowler S. Optimization of experimental conditions of automated glucuronidation assays in human liver microsomes using a cocktail approach and ultra-high performance liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 2019;47(2):124\u201334. https:\/\/doi.org\/10.1124\/dmd.118.084301.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1025_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1124\/dmd.107.019406","volume":"36","author":"G Chen","year":"2008","unstructured":"Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P. Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metab Dispos. 2008;36(5):824\u201330. https:\/\/doi.org\/10.1124\/dmd.107.019406.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1025_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1124\/mol.107.037093","volume":"72","author":"S Kaivosaari","year":"2007","unstructured":"Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol. 2007;72(3):761\u20138. https:\/\/doi.org\/10.1124\/mol.107.037093.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1025_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13318-018-0532-4","volume":"44","author":"TM Conner","year":"2019","unstructured":"Conner TM, Reed RC, Zhang T. A physiologically based pharmacokinetic model for optimally profiling lamotrigine disposition and drug-drug interactions. Eur J Drug Metab Pharmacokinet. 2019;44(3):389\u2013408. https:\/\/doi.org\/10.1007\/s13318-018-0532-4.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"1025_CR12","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1038\/s41598-019-45778-9","volume":"9","author":"MK Ladumor","year":"2019","unstructured":"Ladumor MK, Thakur A, Sharma S, Rachapally A, Mishra S, Bobe P, et al. A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation. Sci Rep. 2019;9(1):9709. https:\/\/doi.org\/10.1038\/s41598-019-45778-9.","journal-title":"Sci Rep"},{"issue":"2","key":"1025_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1124\/jpet.117.245126","volume":"364","author":"T Taghavi","year":"2018","unstructured":"Taghavi T, Arger CA, Heil SH, Higgins ST, Tyndale RF. Longitudinal influence of pregnancy on nicotine metabolic pathways. J Pharmacol Exp Ther. 2018;364(2):238\u201345. https:\/\/doi.org\/10.1124\/jpet.117.245126.","journal-title":"J Pharmacol Exp Ther"},{"key":"1025_CR14","unstructured":"Rowland A. In vitro approaches for predicting inhibitory drug interactions involving glucuronidated drugs: an investigation of the lamotrigine - valproic acid interaction. Flinders University,\u00a0South Australia; 2004."},{"issue":"5","key":"1025_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/clpt.1987.193","volume":"42","author":"AF Cohen","year":"1987","unstructured":"Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987;42(5):535\u201341. https:\/\/doi.org\/10.1038\/clpt.1987.193.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1025_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s002280000146","volume":"56","author":"U Ebert","year":"2000","unstructured":"Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2000;56(4):299\u2013304. https:\/\/doi.org\/10.1007\/s002280000146.","journal-title":"Eur J Clin Pharmacol"},{"key":"1025_CR17","doi-asserted-by":"crossref","unstructured":"Yuen WC, Peck AW. Lamotrigine Pharmacokinetics: Oral and I.V. infusion in man. Epilepsia. 1987;28(5):578\u2013636. http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.1987.tb03691.x\/abstract\n.","DOI":"10.1111\/j.1528-1157.1987.tb03691.x"},{"issue":"9","key":"1025_CR18","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1111\/epi.14519","volume":"59","author":"AR Polepally","year":"2018","unstructured":"Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, et al. Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. Epilepsia. 2018;59(9):1718\u201326. https:\/\/doi.org\/10.1111\/epi.14519.","journal-title":"Epilepsia"},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tiv.2018.12.017","volume":"58","author":"C Fisher","year":"2019","unstructured":"Fisher C, Simeon S, Jamei M, Gardner I, Bois YF. VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays. Toxicol In Vitro. 2019;58:42\u201350. https:\/\/doi.org\/10.1016\/j.tiv.2018.12.017.","journal-title":"Toxicol In Vitro"},{"issue":"Suppl 2","key":"1025_CR20","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1528-1157.1991.tb05883.x","volume":"32","author":"AW Peck","year":"1991","unstructured":"Peck AW. Clinical pharmacology of lamotrigine. Epilepsia. 1991;32(Suppl 2):S9-12. https:\/\/doi.org\/10.1111\/j.1528-1157.1991.tb05883.x.","journal-title":"Epilepsia"},{"issue":"2","key":"1025_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/bdd.2072","volume":"38","author":"D Pade","year":"2017","unstructured":"Pade D, Jamei M, Rostami-Hodjegan A, Turner DB. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. Biopharm Drug Dispos. 2017;38(2):94\u2013114. https:\/\/doi.org\/10.1002\/bdd.2072.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"1025_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/clpt.2008.106","volume":"84","author":"DM Burger","year":"2008","unstructured":"Burger DM, Huisman A, Van Ewijk N, Neisingh H, Van Uden P, Rongen GA, et al. The effect of atazanavir and atazanavir\/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008;84(6):698\u2013703. https:\/\/doi.org\/10.1038\/clpt.2008.106.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1025_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225\u201337. https:\/\/doi.org\/10.1208\/s12248-009-9099-y.","journal-title":"AAPS J"},{"issue":"1","key":"1025_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/138920007779315053","volume":"8","author":"ZE Barter","year":"2007","unstructured":"Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33\u201345. https:\/\/doi.org\/10.2174\/138920007779315053.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"1025_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1124\/dmd.117.079475","volume":"46","author":"B Achour","year":"2018","unstructured":"Achour B, Dantonio A, Niosi M, Novak JJ, Al-Majdoub ZM, Goosen TC, et al. Data generated by quantitative liquid chromatography-mass spectrometry proteomics are only the start and not the endpoint: Optimization of quantitative concatemer-based measurement of hepatic uridine-5\u2019-diphosphate-glucuronosyltransferase enzymes with reference to catalytic activity. Drug Metab Dispos. 2018;46(6):805\u201312. https:\/\/doi.org\/10.1124\/dmd.117.079475.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1025_CR26","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1021\/acs.molpharmaceut.0c00559","volume":"17","author":"A Basit","year":"2020","unstructured":"Basit A, Neradugomma NK, Wolford C, Fan PW, Murray B, Takahashi RH, et al. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol Pharm. 2020;17(11):4114\u201324. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00559.","journal-title":"Mol Pharm"},{"issue":"1","key":"1025_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.1109","volume":"105","author":"DK Bhatt","year":"2019","unstructured":"Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, et al. Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin Pharmacol Ther. 2019;105(1):131\u201341. https:\/\/doi.org\/10.1002\/cpt.1109.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1025_CR28","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1021\/pr4004213","volume":"12","author":"JK Fallon","year":"2013","unstructured":"Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS\/MS with selected reaction monitoring. J Proteome Res. 2013;12(10):4402\u201313. https:\/\/doi.org\/10.1021\/pr4004213.","journal-title":"J Proteome Res"},{"issue":"9","key":"1025_CR29","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1124\/dmd.115.065391","volume":"43","author":"G Margaillan","year":"2015","unstructured":"Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, et al. Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential. Drug Metab Dispos. 2015;43(9):1331\u20135. https:\/\/doi.org\/10.1124\/dmd.115.065391.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1025_CR30","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1124\/dmd.113.056291","volume":"42","author":"Y Sato","year":"2014","unstructured":"Sato Y, Nagata M, Tetsuka K, Tamura K, Miyashita A, Kawamura A, et al. Optimized methods for targeted peptide-based quantification of human uridine 5\u2019-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 2014;42(5):885\u20139. https:\/\/doi.org\/10.1124\/dmd.113.056291.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"1025_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1124\/dmd.121.000474","volume":"49","author":"RH Takahashi","year":"2021","unstructured":"Takahashi RH, Forrest WF, Smith AD, Badee J, Qiu N, Schmidt S, et al. Characterization of hepatic UDP-glucuronosyltransferase enzyme abundance-activity correlations and population variability using a proteomics approach and comparison with cytochrome P450 enzymes. Drug Metab Dispos. 2021;49(9):760\u20139. https:\/\/doi.org\/10.1124\/dmd.121.000474.","journal-title":"Drug Metab Dispos"},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"104601","DOI":"10.1016\/j.jprot.2022.104601","volume":"263","author":"AM Vasilogianni","year":"2022","unstructured":"Vasilogianni AM, El-Khateeb E, Al-Majdoub ZM, Alrubia S, Rostami-Hodjegan A, Barber J, et al. Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease. J Proteomics. 2022;263:104601. https:\/\/doi.org\/10.1016\/j.jprot.2022.104601.","journal-title":"J Proteomics"},{"issue":"5","key":"1025_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/cpt.2558","volume":"111","author":"C Wegler","year":"2022","unstructured":"Wegler C, Wisniewski JR, Robertsen I, Christensen H, Kristoffer Hertel J, Hjelmesaeth J, et al. Drug disposition protein quantification in matched human jejunum and liver from donors with obesity. Clin Pharmacol Ther. 2022;111(5):1142\u201354. https:\/\/doi.org\/10.1002\/cpt.2558.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1025_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11095-014-1525-x","volume":"32","author":"T Yan","year":"2015","unstructured":"Yan T, Gao S, Peng X, Shi J, Xie C, Li Q, et al. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS\/MS method. Pharm Res. 2015;32(3):1141\u201357. https:\/\/doi.org\/10.1007\/s11095-014-1525-x.","journal-title":"Pharm Res"},{"issue":"5","key":"1025_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/cpt.2396","volume":"110","author":"ZM Al-Majdoub","year":"2021","unstructured":"Al-Majdoub ZM, Scotcher D, Achour B, Barber J, Galetin A, Rostami-Hodjegan A. Quantitative proteomic map of enzymes and transporters in the human kidney: stepping closer to mechanistic kidney models to define local kinetics. Clin Pharmacol Ther. 2021;110(5):1389\u2013400. https:\/\/doi.org\/10.1002\/cpt.2396.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1025_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ac201704a","volume":"84","author":"DE Harbourt","year":"2012","unstructured":"Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK, Glish GL, et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84(1):98\u2013105. https:\/\/doi.org\/10.1021\/ac201704a.","journal-title":"Anal Chem"},{"issue":"2","key":"1025_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/jpet.114.220194","volume":"352","author":"S Fowler","year":"2015","unstructured":"Fowler S, Kletzl H, Finel M, Manevski N, Schmid P, Tuerck D, et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352(2):358\u201367. https:\/\/doi.org\/10.1124\/jpet.114.220194.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1025_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/jpet.109.159855","volume":"332","author":"JZ Berg","year":"2010","unstructured":"Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther. 2010;332(1):202\u20139. https:\/\/doi.org\/10.1124\/jpet.109.159855.","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"1025_CR39","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1158\/0008-5472.CAN-09-4582","volume":"70","author":"G Chen","year":"2010","unstructured":"Chen G, Giambrone NE Jr, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res. 2010;70(19):7543\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4582.","journal-title":"Cancer Res"},{"issue":"3","key":"1025_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/dmd.119.089482","volume":"48","author":"N Milani","year":"2020","unstructured":"Milani N, Qiu N, Molitor B, Badee J, Cruciani G, Fowler S. Use of phenotypically poor metabolizer individual donor human liver microsomes to identify selective substrates of UGT2B10. Drug Metab Dispos. 2020;48(3):176\u201386. https:\/\/doi.org\/10.1124\/dmd.119.089482.","journal-title":"Drug Metab Dispos"},{"key":"1025_CR41","doi-asserted-by":"publisher","first-page":"1004010","DOI":"10.3389\/fphar.2022.1004010","volume":"13","author":"MM Fashe","year":"2022","unstructured":"Fashe MM, Fallon JK, Miner TA, Tiley JB, Smith PC, Lee CR. Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes. Front Pharmacol. 2022;13:1004010. https:\/\/doi.org\/10.3389\/fphar.2022.1004010.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1025_CR42","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1124\/dmd.109.026609","volume":"37","author":"H Chen","year":"2009","unstructured":"Chen H, Yang K, Choi S, Fischer JH, Jeong H. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009;37(9):1841\u20137. https:\/\/doi.org\/10.1124\/dmd.109.026609.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1025_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/futurepharmacol4020018","volume":"4","author":"M Berezowska","year":"2024","unstructured":"Berezowska M, Coppola P, Pilla Reddy V, Sharma P. Physiologically based pharmacokinetic modelling of UGT substrate drugs lamotrigine and raltegravir during pregnancy. Future Pharmacol. 2024;4(2):317\u201335. https:\/\/doi.org\/10.3390\/futurepharmacol4020018.","journal-title":"Future Pharmacol"},{"issue":"12","key":"1025_CR44","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/004982598238895","volume":"28","author":"GT Tucker","year":"1998","unstructured":"Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica. 1998;28(12):1255\u201373. https:\/\/doi.org\/10.1080\/004982598238895.","journal-title":"Xenobiotica"},{"issue":"2","key":"1025_CR45","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1124\/jpet.301.2.594","volume":"301","author":"D Dempsey","year":"2002","unstructured":"Dempsey D, Jacob P 3rd, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther. 2002;301(2):594\u20138. https:\/\/doi.org\/10.1124\/jpet.301.2.594.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"1025_CR46","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/psp4.13045","volume":"12","author":"YT Huang","year":"2023","unstructured":"Huang YT, Huang YM, Kung FL, Lin CJ, Jao T, Ho YF. Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact. CPT: Pharmacometrics Syst Pharmacol. 2023;12(12):1960\u201371. https:\/\/doi.org\/10.1002\/psp4.13045.","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1025_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2125.1989.tb03514.x","volume":"28","author":"J Posner","year":"1989","unstructured":"Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert\u2019s syndrome). Br J Clin Pharmacol. 1989;28(1):117\u201320. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03514.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1025_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1055\/s-0031-1296641","volume":"57","author":"T Incecayir","year":"2007","unstructured":"Incecayir T, Agabeyoglu I, Gucuyener K. Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. Arzneimittelforschung. 2007;57(8):517\u201321. https:\/\/doi.org\/10.1055\/s-0031-1296641.","journal-title":"Arzneimittelforschung"},{"issue":"10","key":"1025_CR49","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0091270009345689","volume":"49","author":"M van Luin","year":"2009","unstructured":"van Luin M, Colbers A, Verwey-van Wissen CP, van Ewijk-Beneken-Kolmer EW, van der Kolk M, Hoitsma A, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol. 2009;49(10):1220\u20137. https:\/\/doi.org\/10.1177\/0091270009345689.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1025_CR50","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00228-003-0558-6","volume":"58","author":"R Hermann","year":"2003","unstructured":"Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2003;58(12):795\u2013802. https:\/\/doi.org\/10.1007\/s00228-003-0558-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1025_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2125.1997.tb00028.x","volume":"43","author":"R Wootton","year":"1997","unstructured":"Wootton R, Soul-Lawton J, Rolan PE, Sheung CT, Cooper JD, Posner J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol. 1997;43(1):23\u20137. https:\/\/doi.org\/10.1111\/j.1365-2125.1997.tb00028.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1025_CR52","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1528-1167.2007.01037.x","volume":"48","author":"S Chien","year":"2007","unstructured":"Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, et al. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia. 2007;48(7):1328\u201338. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01037.x.","journal-title":"Epilepsia"},{"issue":"5","key":"1025_CR53","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1592\/phco.26.5.627","volume":"26","author":"MW Jann","year":"2006","unstructured":"Jann MW, Hon YY, Shamsi SA, Zheng J, Awad EA, Spratlin V. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy. 2006;26(5):627\u201333. https:\/\/doi.org\/10.1592\/phco.26.5.627.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1025_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/j.1552-4604.1996.tb04228.x","volume":"36","author":"R Colucci","year":"1996","unstructured":"Colucci R, Glue P, Holt B, Banfield C, Reidenberg P, Meehan JW, et al. Effect of felbamate on the pharmacokinetics of lamotrigine. J Clin Pharmacol. 1996;36(7):634\u20138. https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04228.x.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1025_CR55","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1365-2125.2006.02598.x","volume":"61","author":"J Sidhu","year":"2006","unstructured":"Sidhu J, Job S, Bullman J, Francis E, Abbott R, Ascher J, et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol. 2006;61(4):420\u20136. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02598.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1025_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clpt.2006.04.014","volume":"80","author":"MJ van der Lee","year":"2006","unstructured":"van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir\/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80(2):159\u201368. https:\/\/doi.org\/10.1016\/j.clpt.2006.04.014.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1025_CR57","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/00007691-200012000-00003","volume":"22","author":"RG Morris","year":"2000","unstructured":"Morris RG, Black AB, Lam E, Westley IS. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit. 2000;22(6):656\u201360. https:\/\/doi.org\/10.1097\/00007691-200012000-00003.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1025_CR58","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.eplepsyres.2011.02.002","volume":"94","author":"A Reimers","year":"2011","unstructured":"Reimers A, Helde G, Brathen G, Brodtkorb E. Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res. 2011;94(3):198\u2013205. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.02.002.","journal-title":"Epilepsy Res"},{"issue":"7","key":"1025_CR59","doi-asserted-by":"publisher","first-page":"e01315","DOI":"10.1002\/brb3.1315","volume":"9","author":"Y Ding","year":"2019","unstructured":"Ding Y, Tan X, Zhang S, Guo Y. Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. Brain Behav. 2019;9(7):e01315. https:\/\/doi.org\/10.1002\/brb3.1315.","journal-title":"Brain Behav"},{"issue":"1","key":"1025_CR60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eplepsyres.2009.02.011","volume":"85","author":"C Fotopoulou","year":"2009","unstructured":"Fotopoulou C, Kretz R, Bauer S, Schefold JC, Schmitz B, Dudenhausen JW, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85(1):60\u20134. https:\/\/doi.org\/10.1016\/j.eplepsyres.2009.02.011.","journal-title":"Epilepsy Res"},{"issue":"22 Pt 2","key":"1025_CR61","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","volume":"70","author":"PB Pennell","year":"2008","unstructured":"Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70(22 Pt 2):2130\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000289511.20864.2a.","journal-title":"Neurology"},{"issue":"1","key":"1025_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yebeh.2013.06.026","volume":"29","author":"TL Reisinger","year":"2013","unstructured":"Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013;29(1):13\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2013.06.026.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 1","key":"1025_CR63","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/jcph.1493","volume":"59","author":"J Badee","year":"2019","unstructured":"Badee J, Qiu N, Collier AC, Takahashi RH, Forrest WF, Parrott N, et al. Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes. J Clin Pharmacol. 2019;59(Suppl 1):S42\u201355. https:\/\/doi.org\/10.1002\/jcph.1493.","journal-title":"J Clin Pharmacol"},{"key":"1025_CR64","doi-asserted-by":"publisher","unstructured":"Costa B, Gouveia MJ, Vale N. PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for personalized dosing and drug-drug interaction management. Pharmaceutics. 2024;16(9). https:\/\/doi.org\/10.3390\/pharmaceutics16091163.","DOI":"10.3390\/pharmaceutics16091163"},{"issue":"5","key":"1025_CR65","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1124\/dmd.117.079921","volume":"46","author":"A Labriet","year":"2018","unstructured":"Labriet A, Allain EP, Rouleau M, Audet-Delage Y, Villeneuve L, Guillemette C. Post-transcriptional regulation of UGT2B10 hepatic expression and activity by alternative splicing. Drug Metab Dispos. 2018;46(5):514\u201324. https:\/\/doi.org\/10.1124\/dmd.117.079921.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1025_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/2045125316672573","volume":"7","author":"P Douglas-Hall","year":"2017","unstructured":"Douglas-Hall P, Dzahini O, Gaughran F, Bile A, Taylor D. Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust. Ther Adv Psychopharmacol. 2017;7(1):17\u201324. https:\/\/doi.org\/10.1177\/2045125316672573.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"12","key":"1025_CR67","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2217\/pgs.11.105","volume":"12","author":"J Zhou","year":"2011","unstructured":"Zhou J, Argikar UA, Remmel RP. Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics. 2011;12(12):1671\u20139. https:\/\/doi.org\/10.2217\/pgs.11.105.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"1025_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13318-014-0247-0","volume":"41","author":"A Reimers","year":"2016","unstructured":"Reimers A, Sjursen W, Helde G, Brodtkorb E. Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine. Eur J Drug Metab Pharmacokinet. 2016;41(2):149\u201355. https:\/\/doi.org\/10.1007\/s13318-014-0247-0.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1\u20132","key":"1025_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","volume":"95","author":"MI Gulcebi","year":"2011","unstructured":"Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 2011;95(1\u20132):1\u20138. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.01.016.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1025_CR70","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","volume":"70","author":"Y Chang","year":"2014","unstructured":"Chang Y, Yang LY, Zhang MC, Liu SY. Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China. Eur J Clin Pharmacol. 2014;70(8):941\u20136. https:\/\/doi.org\/10.1007\/s00228-014-1690-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1025_CR71","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.12659\/msm.897626","volume":"22","author":"Z Du","year":"2016","unstructured":"Du Z, Jiao Y, Shi L. Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children. Med Sci Monit. 2016;22:4107\u201313. https:\/\/doi.org\/10.12659\/msm.897626.","journal-title":"Med Sci Monit"},{"issue":"2","key":"1025_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcpt.13120","volume":"124","author":"SC Kim","year":"2019","unstructured":"Kim SC, Kim MG. Meta-analysis of the influence of UGT genetic polymorphisms on lamotrigine concentration. Basic Clin Pharmacol Toxicol. 2019;124(2):163\u20139. https:\/\/doi.org\/10.1111\/bcpt.13120.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"1025_CR73","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/bcp.13646","volume":"84","author":"I Klarica Domjanovic","year":"2018","unstructured":"Klarica Domjanovic I, Lovric M, Trkulja V, Petelin-Gadze Z, Ganoci L, Cajic I, et al. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 2018;84(9):2106\u201319. https:\/\/doi.org\/10.1111\/bcp.13646.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1025_CR74","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bcp.12984","volume":"82","author":"D Milosheska","year":"2016","unstructured":"Milosheska D, Lorber B, Vovk T, Kastelic M, Dolzan V, Grabnar I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016;82(2):399\u2013411. https:\/\/doi.org\/10.1111\/bcp.12984.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1025_CR75","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00228-023-03526-z","volume":"79","author":"N Bozina","year":"2023","unstructured":"Bozina N, Sporis IS, Domjanovic IK, Ganoci L, Simicevic L, Lovric M, et al. Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy. Eur J Clin Pharmacol. 2023;79(8):1117\u201329. https:\/\/doi.org\/10.1007\/s00228-023-03526-z.","journal-title":"Eur J Clin Pharmacol."},{"issue":"6","key":"1025_CR76","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/FTD.0000000000000563","volume":"40","author":"Y Chen","year":"2018","unstructured":"Chen Y, Xu S, Wang Z, Zhao M, Wang H, Lu T, et al. A population pharmacokinetic-pharmacogenetic model of lamotrigine in Chinese children with epilepsy. Ther Drug Monit. 2018;40(6):730\u20137. https:\/\/doi.org\/10.1097\/FTD.0000000000000563.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1025_CR77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0000000000000577","volume":"41","author":"T Suzuki","year":"2019","unstructured":"Suzuki T, Mihara K, Nagai G, Kagawa S, Nakamura A, Nemoto K, et al. Relationship between UGT1A4 and UGT2B7 polymorphisms and the steady-state plasma concentrations of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy. Ther Drug Monit. 2019;41(1):86\u201390. https:\/\/doi.org\/10.1097\/FTD.0000000000000577.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1025_CR78","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.dmpk.2014.12.007","volume":"30","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liang M, Dong Y, Yun W, Qiu F, Zhao L, et al. Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy. Drug Metab Pharmacokinet. 2015;30(3):209\u201313. https:\/\/doi.org\/10.1016\/j.dmpk.2014.12.007.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"11","key":"1025_CR79","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","volume":"71","author":"L Liu","year":"2015","unstructured":"Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y. Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol. 2015;71(11):1341\u20137. https:\/\/doi.org\/10.1007\/s00228-015-1925-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1025_CR80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","volume":"39","author":"RG Greenberg","year":"2016","unstructured":"Greenberg RG, Melloni C, Wu H, Gonzalez D, Ku L, Hill KD, et al. Therapeutic index estimation of antiepileptic drugs: A systematic literature review approach. Clin Neuropharmacol. 2016;39(5):232\u201340. https:\/\/doi.org\/10.1097\/WNF.0000000000000172.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1025_CR81","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","volume":"14","author":"MS Benedetti","year":"2000","unstructured":"Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14(4):301\u201319. https:\/\/doi.org\/10.1111\/j.1472-8206.2000.tb00411.x.","journal-title":"Fundam Clin Pharmacol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01025-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01025-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01025-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:57:03Z","timestamp":1740506223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01025-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01025-w","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IG and ATH are employees of Certara Predictive Technologies and may own Certara Stock. LWTT, KL and TCG are employees of Pfizer Inc., New York, NY, USA and may own shares\/stock options in Pfizer Inc., New York, NY, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"40"}}